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Abstract
Background: Anti-Ab immunotherapy is a promising approach to the prevention and treatment of Alzheimer’s
disease (AD) currently in clinical trials. There is extensive evidence, both in mice and humans that a significant
adverse event is the occurrence of microhemorrhages. Also, vasogenic edema was reported in phase 2 of a passive
immunization clinical trial. In order to overcome these vascular adverse effects it is critical that we understand the
mechanism(s) by which they occur.
Methods: We have examined the matrix metalloproteinase (MMP) protein degradation system in two previously
published anti-Ab immunotherapy studies. The first was a passive immunization study in which we examined 22 month
old APPSw mice that had received anti-Ab antibodies for 1, 2 or 3 months. The second is an active vaccination study in
which we examined 16 month old APPSw/NOS2-/- mice treated with Ab vaccination for 4 months.
Results: There is a significant activation of the MMP2 and MMP9 proteinase degradation systems by anti-Ab
immunotherapy, regardless of whether this is delivered through active vaccination or passive immunization. We have
characterized this activation by gene expression, protein expression and zymography assessment of MMP activity.
Conclusions: Since the MMP2 and MMP9 systems are heavily implicated in the pathophysiology of intracerbral
hemorrhage, these data may provide a potential mechanism of microhemorrhage due to immunotherapy. Increased
activity of the MMP system, therefore, is likely to be a major factor in increased microhemorrhage occurrence.
Keywords: Immunotherapy, matrix metalloproteinases, inflammation, microhemorrhage, amyloid, cerebral amyloid
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Background
Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disorder characterized clinically by a devastating cog-
nitive decline. Pathologically, the three hallmarks of AD
are extracellular amyloid plaques composed of aggregated
Ab peptide, intracellular neurofibrillary tangles composed
of aggregated, hyperphosphorylated tau protein, and neu-
rodegeneration characterized by loss of synapses and
neurons [1]. The prevailing hypothesis for the pathologi-
cal progression of AD is the amyloid hypothesis, and
while it has undergone significant modification over the
years, the basic thought is that the deposition of amyloid
leads to neuronal changes causing the hyperphosphoryla-
tion of tau, which in turn leads to neuronal dysfunction
and ultimately neuron death [2,3].
The amyloid hypothesis has been used as the basis of
disease modifying therapies to treat AD. The most promis-
ing current pharmacological approach in clinical trials is
anti-Ab immunotherapy [4]. There are many ongoing clin-
ical trials currently testing various modes of immunother-
apy including active vaccination, passive immunization
and IVIg therapy. While most data is very encouraging,
including some promising cognitive outcomes [5] and evi-
dence of amyloid reductions through PET imaging [6],
there are vascular adverse events that remain a significant
concern.
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mouse studies [7] and in human clinical trials [5,8].
Immunotherapy has been shown to produce microhe-
morrhages (focused cerebral hemorrhagic events) and
vasogenic edema (a pathological increase in extracellular
fluid volume in the brain caused by damage to the blood
brain barrier). Microhemorrhages have been shown in as
many as twenty mouse studies to date and appear to
require the presence of vascular amyloid deposition, a
primary factor in cerebral amyloid angiopathy (CAA).
The microhemorrhages occur regardless of whether the
immunotherapy is active [9] or passive [10-13], yet the
mechanism by which they occur is unknown. Vasogenic
edema is an MRI phenomenon that has been observed in
the ongoing bapineuzumab human clinical trial [6,14-16].
Its onset is more prevalent in ApoE4 carriers and its
mechanism is unknown.
The focus of the current study was to examine changes
in the MMP system in response to anti-Ab immunother-
apy. MMP2 and MMP9 are heavily implicated in the
occurrence of cerebral hemorrhage [17-21], and MMP9 is
induced by multiple inflammatory cytokines [22-24]. The
MMP2 and 9 systems are complex, and involve a series of
enzymatic cleavages to create the final active form of the
enzyme (Figure 1). Briefly, MMP2 and MMP9 are released
as a pro-enzyme that require enzymatic cleavage to be
active. Pro-MMP2 is cleaved by MT1-MMP while pro-
MMP9 is cleaved by MMP3. Both MMP2 and MMP9
have endogenous inhibitors, called TIMP1 and TIMP2
respectively (where TIMP = tissue inhibitor of metallopro-
teinases). We show that the MMP2 and MMP9 systems
are activated following both passive and active anti-Ab
immunotherapy. The MMP changes only occur in mice
that show significant microhemorrhage due to immu-
notherapy, indicating a critical role for the MMPs in the
induction of microhemorrhage.
Methods
Transgenic mice
The study was approved by the Duke University Institu-
tional Animal Care and Use Committee and conformed to
the National Institutes of Health Guide for the Care and
Use of Animals in Research. The APPSw mice (Tg2576,
Swedish K760N/M671L [25]) were bred and housed by
the Morgan-Gordon laboratory at the University of South
Florida. The APPSw/NOS2
-/- mice were produced by
crossing APPSw (Tg2576, Swedish K760N/M671L) trans-
genic mice [25] with NOS2
-/- (B6 129P2NOS2
tau1Lau/J)
mice (Jackson Laboratory, Bar Harbor, ME), as described
previously [26].
Active vaccination study
This study was previously published [9]. To summarize,
APPSw/NOS2-/- and NOS2-/- mice aged 12 months
were assigned to one of two treatment groups. Final
sample sizes were 6 APPSw/NOS2
-/- mice receiving con-
trol vaccination, 6 APPSw/NOS2
-/- mice receiving Ab
vaccination, 6 NOS2
-/- mice receiving control vaccina-
tion and 6 NOS2
-/- mice receiving Ab vaccination. All
mice received 4 vaccinations over a 4 month period. Ab
and KLH vaccinations used complete Freund’s adjuvant
for the first innoculation and incomplete Freund’sa d j u -
vant for the remaining innoculations.
Passive immunization study
This study was previously published [27]. To summar-
ize, 19 month old APPSw mice were assigned to one of
four groups, control antibody for 3 months or anti-Ab
antibody 2286 (Rinat Neurosciences, San Francisco CA)
for one, two or three months (N = 4/group). The start
of dosing was staggered such that all mice were the
same age (22 months) at sacrifice. In the current study
we examined four mice for each treatment group.
Tissue processing
Active vaccination study: After injection with a lethal dose
of ketamine, the mice were perfused intracardially with 25
ml normal saline. Brains were rapidly removed and
bisected in the mid-sagittal plane. One half of each brain
was immersion fixed in 4% paraformaldehyde, while
the other was snap-frozen in liquid nitrogen and stored at
-80°C. Frozen sections of the fixed hemibrain were col-
lected following cryoprotection through sucrose. 25 μm
sections were collected and stored in DPBS+sodium azide
at 4°C until needed. The frozen hemibrain was pulverized
using a mortar and pestle on dry ice. Brain powder was
then stored at -80°C until needed. Passive immunization
study: After injection with a lethal dose of pentobarbital,
the mice were perfused intracardially with 25 ml normal
saline. Brains were rapidly removed and bisected in the
mid-sagittal plane. One half of each brain was immersion
fixed in 4% paraformaldehyde, while the other was dis-
sected into frontal cortex, posterior cortex, hippocampus,
cerebellum and rest of remaining brain tissue. These
pieces were flash frozen and stored at -80°C.
Eight 25 μm sections equally spaced 600 mm apart
were selected from our active vaccination study for free
floating immunohistochemistry for MMP9 (1: 1000,
Rabbit polyclonal, Millipore, Billireca, MA) as described
previously [27].
Quantitative real-time RT-PCR
Approximately 40 mg frozen brain powder (for the active
vaccination study) or the whole right hippocampus (for
the passive immunization study) was used for RNA
extraction using the PerfectPure RNA tissue kit (5 Prime
Inc., Gaithersburg, MD). RNA concentrations were deter-
mined by UV spectrophotometry and cDNA produced
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City, CA). Real-time PCR was performed using the
TaqMan Gene Expression assay kit (Applied Biosystems,
Foster City, CA) according to the manufacturer’s instruc-
tions and as previously described [28]. All genes are nor-
malized to 18 S rRNA. Normaln o n - t r a n s g e n i cm i c e
served as the comparator and fold changes were calcu-
lated using the
-delta delta Ct) method [29] The following
genes were analyzed: 18 s (Hs99999901_s1), MMP2
(Mm00439498_m1), MMP3 (Mm00440295_m1), MMP9
(Mm00600163_m1), MT1-MMP (Mm00485054_m1),
TIMP1 (Mm00441818_m1), TIMP2 (Mm00441825_m1).
ELISA measurement
Active vaccination study only: Protein was extracted from
4 brains for each genotype using 100 mg pulverized brain
powder in PBS with complete protease inhibitor (Sigma-
Aldrich, St Louis MO) and quantified using the BCA pro-
tein assay kit (Pierce Biotechnology Inc. Rockford, IL, per-
formed according to manufacturer’s instructions). We
used commercially available kits to assess MMP3, MMP9,
TIMP1, MMP2 and TIMP2 and ran the assays according
to manufacturer’s recommendations (R&D Systems,
Minneapolis, MN). All data were normalized to the total
protein to yield ng/mg protein.
Zymography
Enzymatic activities of tissue MMPs were measured using
zymography in brain samples from the active vaccination
study only: Protein was extracted using 100 mg pulverized
brain powder in PBS and quantified immediately using the
BCA protein assay kit (Pierce Biotechnology Inc. Rockford,
IL. Performed according to manufacturer’s instructions).
Protein samples were immediately separated on a precast
10% gelatin zymogram gel (Invitrogen, Carlsbad, CA). The
gel was removed, incubated in zymogram renaturing buf-
fer for 30 minutes, equilibrated for 30 minutes in zymo-
gram developing buffer at room temperature and then
incubated overnight at 37°C with gently agitation in fresh
zymogram developing buffer (all buffers obtained from
Invitrogen, Carlsbad, CA). The next day, the gel was
washed gently with water and incubated in Commassie
blue (0.1% Commassie blue, 20% methanol, 10% acetic
acid). The gel was stained for one hour and then destained
using a 50% methanol, 10% acetic acid solution until clear
bands were resolved (approximately 15 minutes). The gel
Figure 1 Schematic of the MMP2 and MMP9 systems. MMP2 is released in its pro form and cleavage by MT1-MMP leads to MMP2 activation.
MT1-MMP is induced by furin and plasmin. TIMP2, tissue inhibitor of metalloproteinases 2, is an endogenous inhibitor of active MMP2. MMP3 is
released in its pro form and cleavage leads to its activation. In turn, MMP9 is released in its pro form and MMP3 cleaves pro-MMP9 to produce
active MMP9. Both pro-MMP3 and pro-MMP9 are induced by pro-inflammatory cytokines such as TNFa and IL-1b. TIMP1 is the endogenous
inhibitor of active MMP9. Both MMP2 and MMP9 are known to degrade extracellular matrix proteins as well as tight junction proteins leading to
vascular leakage and hemorrhage.
Wilcock et al. Journal of Neuroinflammation 2011, 8:115
http://www.jneuroinflammation.com/content/8/1/115
Page 3 of 13was placed in a drying rack to dry and then imaged using
the Kodak imager as described previously [30]. Two gels
were necessary to include all samples. Densitometry was
performed on the two gels and within each gel, data were
normalized to the NOS2-/- band on the corresponding gel
before being combined.
BV2 microglial cell treatment
BV2 microglia were cultured as previously described [28].
The cells were split and plated into 6-well dishes and
grown to confluency. The day prior to treatment we pre-
pared the Ab1-42 by bringing into solution according to
manufacturers’ directions (rPeptide, Bogart, GA). The Ab
was brought to a concentration of 5 μg/ml in PBS. This
solution was then incubated at 37°C overnight to allow
fibrils to form. To form an immune complex, Ab aggre-
gates in solution (5 μg/ml) were incubated with 10 μg/ml
anti-Ab monoclonal antibody 6E10 for 1 hr at 37°C, cen-
trifuged at 100,000 × g for 30 min, and resuspended to ori-
ginal volume as described previously [31] Tau immune
complexes were formed using the same methods, tau pro-
tein at a concentration of 5 μg/ml (rPeptide, Bogart, GA)
was incubated with 10 μg/ml anti-tau monoclonal anti-
body (Clone T14, Invitrogen, Carlsbad, CA) for 1 hr at
37°C, centrifuged at 100,000 × g for 30 min and resus-
pended to original volume. Cells were then treated with
1 ml of the culture media containing 100 μlo fe i t h e r
2.5 μg/ml Ab1-42, 5 mg/ml anti-Ab IgG 6E10, the Abeta
immune complex or the tau immune complex solution.
Sister wells of BV2 cells were treated with fresh media
changes at the same times as the treated cells and served
as untreated controls. The cells were then incubated over-
night. The following day the media was removed and the
cells were washed with PBS and stored at -80°C until
needed. qPCR and ELISAs were run in the same way as
described above for the mouse samples.
Analysis
Data are presented as mean ± standard error of mean
(SEM). Statistical analysis was performed using the JMP
statistical analysis program (SAS, Cary NC). Where
appropriate, student’s t test was performed. Statistical
significance was assigned where the P-value was lower
than 0.05.
Results
Prussian blue is a histochemical staining method used to
detect hemosiderin deposits, indicative of a location of a
prior bleed. These data for both active vaccination and
passive immunization have been previously published
and are summarized in Table 1. A 10-fold increase was
observed in the number of microhemorrhages in APPSw/
NOS2-/- mice receiving Ab vaccination as compared to
APPSw/NOS2-/- mice receiving control vaccination
(Table 1). Our previously published passive immuniza-
tion study in APPSw mice also showed a significant
increase in microhemorrhage occurrence [11]. The
microhemorrhages following passive immunization
occurred in a time dependent manner, where no increase
was observed following one month of treatment, yet after
two and three months of immunization a 6-fold increase
in microhemorrhage was observed (Table 1). An increase
in CAA was only observed in the passively immunized
APPSw mice and we saw no change in CAA in the
actively vaccinated APPSw/NOS2-/- mice. We believe
this could be due to either the difference in mouse strain
or the difference in age; the APPSw mice were signifi-
cantly older and had significantly more CAA at the
beginning of the study than did the APPSw/NOS2-/-.
Quantitative real-time RT-PCR analysis of the levels of
mRNA for the MMP2 system (Figure 2) in APPSw/
NOS2-/- mice receiving KLH control vaccination showed
no significant change compared to non-transgenic mice.
In contrast, Ab vaccination of APPSw/NOS2-/- mice sig-
nificantly increased furin mRNA (a precursor to the acti-
vation of MMP2) but had no effect on MT1-MMP
expression. Importantly, MMP2 mRNA levels were signifi-
cantly increased compared to KLH treated mice while the
endogenous inhibitor of MMP2, TIMP2, showed a signifi-
cant decrease following Ab vaccination (Figure 2A). To
confirm that the gene expression data resulted in mean-
ingful protein changes we performed ELISA measure-
ments from brain lysate for MMP2 and TIMP2 using
commercially available kits.T h eE L I S Am e a s u r e m e n t s
confirmed a statistically significant increase in MMP2 fol-
lowing Ab vaccination, while TIMP2 was significantly
decreased in comparison to KLH control vaccinated
APPSw/NOS2-/- mice (Figure 2B).
The MMP9 system is also an important mediator of
proteolytic activity that may lead to cerebral hemorrhage.
Quantitative real-time RT-PCR analysis of the MMP9 sys-
tem (see Figure 1) in APPSw/NOS2-/- mice receiving con-
trol vaccination showed that MMP9 and TIMP1 mRNA
levels were increased compared to non-transgenic
(NonTg) (Figure 3A). When compared to KLH control
mice, MMP3 mRNA levels in Ab vaccinated APPSw/
NOS2-/- mice increased while MMP9 mRNA remained
unchanged. In contrast, TIMP1 mRNA levels significantly
decreased. Brain lysates were also analyzed for MMP3,
MMP9 and TIMP1 protein levels as described in the
methods. Both MMP3 and MMP9 levels were significantly
increased in in APPSw/NOS2-/- mice following Ab vacci-
nation, while TIMP1 remained unchanged (Figure 3B).
The sensitivities of the methods for measuring protein and
gene expression are different and therefore it is not neces-
sarily surprising that the MMP9 elevation in protein
expression was not significant while the gene expression
was and vice-versa for the TIMP1. It would be speculation
Wilcock et al. Journal of Neuroinflammation 2011, 8:115
http://www.jneuroinflammation.com/content/8/1/115
Page 4 of 13at this point to suggest there may be significant differences
between mRNA and translation to protein, however, this is
a possibility. Importantly, is that the RNA and protein pat-
terns remain consistent.
While quantitative real-time RT-PCR and ELISA can
provide estimates of the total RNA and protein expres-
sion levels of various MMPs, these methods do not pro-
vide a direct measure of the activity of these systems.
Consequently, we performed gelatin zymography to
assess the individual activity of MMP2 or MMP9. Band
densities corresponding to the molecular weights of the
pro and active forms of each enzyme were measured to
provide semi-quantitative measurements of activity. As
can be seen in Figure 4, bands indicative of gelatin degra-
dation are observed at molecular weights of 67, 72, 84
and 92 KDa (Figure 4A). These correspond to active
MMP2, pro-MMP2, active MMP9 and pro-MMP respec-
tively. It is clear from examination of the gel that Ab vac-
cinated APPSw/NOS2-/- mice show bands of a greater
density corresponding to active MMP2 and active
MMP9. Indeed, densitometry analysis showed a
statistically significant increase in MMP2 and MMP
activity in Ab vaccinated mice compared to both
NOS2-/- and control vaccinated APPSw/NOS2-/- mice
(Figure 4B).
To determine whether the cell-specific induction of
MMP9 expression changed with Ab vaccination, we
examined the type of cell and the cellular pattern for
total MMP9 expression using immunohistochemistry.
Low intensity staining of neurons was observed in non-
transgenic mice at 52 weeks of age. There was no detect-
able immunopositive staining in cells around the cereo-
brovasculature (Figure 5 panels A and B). APPSw/
NOS2-/- mice receiving control vaccination showed lar-
gely the same staining pattern as NonTg mice, however,
the staining intensity of neurons appeared slightly greater
(Figure 5 panels C and D). Following Ab vaccination
robust expression of MMP9 was found in association
with the vasculature in all Ab vaccinated APPSw/
NOS2-/- mice. Figure 5E shows extensive staining of
capillaries in the parietal cortex, highlighted by arrows. In
addition, Figure 5F shows an example of an intensely
Table 1 Summary of previously published data for anti-Ab immunotherapy studies
Study Mouse model Age (mo) Histopathology Cognition
Ab CAA Micro-hemorrhage
Passive immunization APPSw 19-22 ↓60% ↑ 4-fold ↑ 6-fold Improved
Active vaccination APPSw/
NOS2-/-
12-16 ↓85% No change ↑ 10-fold Reversed
Figure 2 Active Ab vaccination in APPSw/NOS2-/- mice activates the MMP2 system. Panel A shows the average #177; SEM) fold change in
mRNA for components of the MMP2 system in APPSw/NOS2-/- mice vaccinated with either KLH or Ab for 4 months. Furin and MMP2 are all
significantly increased following vaccination while TIMP2 is significantly decreased. The dashed line indicates the average mRNA of the non-
transgenic control mice. * indicates P < 0.05, ** indicates P < 0.01 compared to KLH vaccinated APPSw/NOS2-/- mice. Panel B shows the average
#177; SEM) protein levels of MMP2 and TIMP2 as measured by sandwich ELISA. Data are normalized to the protein concentration of the tissue
homogenate. ** indicates P < 0.01 compared to KLH vaccinated APPSw/NOS2-/- mice.
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of an Ab vaccinated APPSw/NOS2-/- mouse.
In order to confirm that the changes in the MMP sys-
tems were due to anti-Ab immunotherapy and not
unique to our study in APPSw/NOS2-/- mice, we per-
formed quantitative real-time RT-PCR of APPSw mice
that had been passively immunized and shown to have
significant Ab reductions, cognitive improvements and
inflammatory changes (Table 1 and [27]). We examined
components of both the MMP2 and MMP9 systems and
found strikingly similar patterns to the data in the
actively vaccinated APPSw/NOS2-/- mice. Interestingly,
the MMP2 system showed changes that were dependent
on the duration of passive immunization treatment. Fol-
lowing one month of immunization, APPSw mice
showed increased gene expression of MMP2 that
remained elevated at 2 and 3 months (Figure 6A). After a
slight elevation at 1 month, furin levels transiently
decreased thereafter while TIMP2 mRNA levels signifi-
cantly decreased from the 1 month time point. Thus
after two months of immunization which is the time at
which we observe significant microhemorrhage under
these conditions, we find that MMP2 gene expression
remains significantly elevated, while furin and TIMP2 are
significantly decreased (Figure 6A). If protein expression
and activity follows the changed gene expression, these
results would suggest an increased enzymatic activity of
MMP2 due to less inhibitor. Finally, the MMP9 system is
also activated following passive immunization. Interest-
ingly, following one month of immunization, gene
expression of MMP3 and MMP9 are not largely affected,
yet there is a significant increase in the MMP9 inhibitor,
TIMP1 (Figure 6B). Importantly, we do not observe
microhemorrhage at this time point. By two months of
immunization MMP3 and MMP9 are significantly
increased and although not reaching statistical signifi-
cance, TIMP1 is reduced compared to the one month
time point (Figure 6B). This pattern is also retained for
the three months of immunization.
Finally, to establish if MMP expression was induced via
Fcg-receptor signaling we treated BV2 microglial cultures
with anti-Ab IgG alone, Ab1-42 fibrils, anti-Ab IgG/Ab
immune complexes or anti-tau/tau immune complexes
and compared the gene expression changes for various
MMPs. Three separate culture groups were tested and
separate wells of the same culture were used to extract
RNA for gene expression analysis and protein for ELISA
measurements. We found that IgG treatment of BV2 cells
selectively stimulated the induction of MT1-MMP of the
MMP2 system as determined by qRT-PCR (Figure 7A).
No component of the MMP9 system was activated by IgG
treatment (Figure 7C and 7D). Ab fibril treatment stimu-
lated both MT1-MMP and MMP2 of the MMP2 system
as measured by qRT-PCR (Figure 7A), ELISA measure-
ment of MMP2 confirmed this change (Figure 7B).
Ab treatment increased TIMP1 expression significantly
but no other changes were noted with respect to the
MMP9 system (Figure 7C and 7D). Interestingly, treat-
ment of BV2 cells with anti-Ab IgG-Ab or anti-tau IgG-
tau immune complexes resulted in a significant reduction
of TIMP2, the inhibitor of MMP2 at the RNA and protein
level, and also activation of the MMP9 system including
increased expression of MMP3 and MMP9 as measured
by qRT-PCR and ELISA (Figures 7C and 7D). The
Figure 3 Active Ab vaccination in APPSw/NOS2-/- mice activates the MMP9 system. Panel A shows the average (± SEM) fold change for
components of the MMP9 system in mice vaccinated with either KLH or Ab for 4 months. MMP3 and MMP9 are significantly increased. The
dashed line indicates the average gene expression of the non-transgenic control mice. ** indicates P < 0.01 compared to KLH vaccinated
APPSw/NOS2-/- mice. Panel B shows the average (± SEM) protein levels of MMP3, MMP9 and TIMP1 as measured by sandwich ELISA. Data are
normalized to the protein concentration of the tissue homogenate. ** indicates P < 0.01 compared to KLH vaccinated APPSw/NOS2-/- mice.
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Page 6 of 13Figure 4 Active Ab vaccination in APPSw/NOS2-/- mice leads to increased activity of MMP2 and MMP9 as measured by gelatin
zymography. Panel A shows a representative image of the gelatin zymogram. The white bands indicate where the gelatin has been degraded
by the proteinase. Based on the molecular weights of pro-MMP9, MMP9, pro-MMP2 and MMP2 we performed densitometry measurements on
the white bands corresponding to these proteinases. Panel B shows the average (± SEM) densitometry quantification of the zymography bands.
Data are shown as the fold-change from the average of the NOS2-/-densitometry data. Total sample size is N = 6 for NOS2-/-, N = 7 for KLH
vaccinated and N = 7 for ABeta vaccinated. ** indicates P < 0.01 compared to KLH vaccinated.
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Page 7 of 13Figure 5 Active Ab vaccination in APPSw/NOS2-/- mice leads to increased total MMP9 expression at the cerebrovasculature. Panels A
and B show representative total MMP9 immunohistochemcial staining from non-transgenic mice. Lightly stained neurons can be found
throughout the brain but there is no discernable vascular staining. Panels C and D show representative total MMP9 immunohistochemcial
staining from APPSw/NOS2-/- receiving KLH vaccination for 4 months. Again, there are lightly stained neurons throughout the brain but no
discernable vascular staining. Panels E and F show representative total MMP9 immunohistochemcial staining from APPSw/NOS2-/- mice receiving
Ab vaccination. In addition to the lightly stained neurons these mice show extensive MMP9 immunostaining at the cerebrovasculature,
specifically capillaries (indicated by arrows in panel E) and penetrating arteries (indicated by the arrow in panel F). Panels A-F magnification =
200×, scale bar panel A for A-F = 25 μm.
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this was Ab immune complex or tau immune complex,
was the only treatment to activate the MMP9 system indi-
cating a requirement for Fcg-receptor signaling through
opsonized antigen.
Discussion
Microhemorrhages are a significant consequence of cere-
bral amyloid angiopathy (CAA) and based on MRI detec-
tion, are known to occur in as many as 40% of AD cases
[32]. As imaging techniques become more sensitive, this
percentage may become even higher. In addition, microhe-
morrhages are exacerbated by anti-Ab immunotherapy in
mouse and human studies [8,10-13]. Another vascular
adverse event of immunotherapy is vasogenic edema,
which has been found in the ongoing immunotherapy trial
of bapineuzumab [5]. Vasogenic edema involves disruption
of the blood-brain barrier and may therefore share a com-
mon mechanism of action with microhemorrhages. While
a number of pathophysiological factors may contribute to
microhemorrhage and vasogenic edema, proteolytic desta-
bilization of the neurovascular unit may be an important
feature. Matrix metalloproteinases are a family of protei-
nases known to degrade components of extracellular
matrix, as well as other proteins including cytokines and
pro/anti-angiogenic modulators. In particular, MMP2 and
MMP9 are implicated in cerebrovascular dysfunction.
Using mouse models of AD, we have examined changes in
these MMP systems with immunotherapy in two separate
studies, an active vaccination study and a passive immuni-
zation study, both of which have shown increased inci-
dence of microhemorrhage.
MMP2 is also known as gelatinase A and is secreted as
ap r o - f o r m ,w h i c hr e q u i r e sc l e a v a g eb yM T 1 - M M P
(MMP14) for its activation [33]. MT1-MMP is activated
by furin and plasmin. In addition, plasmin has been
shown to directly activate surface-bound pro-MMP2
[34]. An endogenous inhibitor of MMP2, TIMP2, con-
trols the activity of MMP2 post-translationally [35].
Importantly, MMP2 has been shown to be involved in
the early opening of the blood brain barrier following
cerebral reperfusion [36,37]. This MMP2-mediated pro-
cess involves degradation of the tight junction protein,
claudin-5 [37].
In order to evaluate the activity of the MMP2 system in
our mouse models of AD, we examined the gene and cor-
responding protein expression levels of furin, MT1-MMP,
MMP2 and TIMP2 in mice that received active Ab vacci-
nation. We found that vaccination resulted in increased
gene expression of furin, and MMP2 along with a conco-
mitant decrease in TIMP2 expression, while protein
expression followed the same pattern. In addition, we
established that MMP2 activity was significantly increased
by performing gelatin zymography on brain lysates. These
observed changes are consistent with an increase in pro-
teolytic activity that may degrade collagen or other extra-
cellular matrix proteins that comprise the blood brain
barrier, leading to leakage of cerebral vessels. To confirm
that our findings were relevant to immunotherapy, we
Figure 6 Passive immunization in APPSw mice leads to a rapid
activation of the MMP2 system as well as a later activation of
the MMP9 system. Panels A and B show relative gene expression
analysis of the hippocampus of APPSw mice receiving control
antibody for 3 months or anti-Ab antibody for 1, 2 and 3 months.
Data are shown as the average (± SEM) fold change in mRNA. Panel
A shows data for the MMP2 system, panel B shows data from the
MMP9 system. * indicates P < 0.05, ** indicates P < 0.01 compared
to control antibody treated mice.
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passively immunized and showed significant microhemor-
rhage incidence [11,27]. Indeed we found similar trends in
passively immunized mice as compared to the actively vac-
cinated mice. Following one month of immunization
MMP2 was increased and for the following two and three
months only the MMP2 remained significantly elevated.
TIMP2 levels, however, transiently and slightly increased
at 1 month then remained at a reduced level. While it may
seem that the active vaccination had a lesser effect on the
MMP2 system than the passive immunization, it is impor-
tant that we not draw conclusions from this since these
are different strains of mice (APPSw/NOS2-/- vs. APPSw)
and different aged mice (16 vs. 22 months). All of these
things could account for the apparent smaller effect size in
the active vaccination study. Overall, the MMP2 system
data suggest that increased activity of the MMP2 system
m a yb ei n v o l v e di na b n o r m a lp roteolytic activity at the
neurovascular interface.
The second major proteolytic enzyme in the brain,
MMP9 (also known as gelatinase B), has been heavily
implicated in many types of CNS injury including stroke
[38], ischemia [35] and trauma [39]. The normal function
of MMP9 is degradation of extracellular matrix to allow
for cell migration and also degradation of basement
membranes to allow for cell movement across the blood
Figure 7 Treatment of BV2 microglial cells with immune complexes leads to induction of components of the MMP2 and MMP9
systems. Panels A and C show the average (± SEM) mRNA levels of the MMP2 (A) and MMP9 (C) systems in BV2 cells treated with IgG, Abeta,
Abeta immune complexes (Abeta IC) or tau immune complexes (tau IC) for 24 hours. Data are shown as fold change compared to untreated
sister BV2 cultures. * indicates P < 0.05, ** indicates P < 0.01 compared to untreated BV2 cells. Panels B and D show protein expression as
measured by sandwich ELISA for components of the MMP2 (B) and MMP9 (D) systems. * indicates P < 0.05, ** indicates P < 0.01 compared to
untreated BV2 cells.
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i n d i c a t i n gar o l ei nA b homeostasis [40]. MMP9 is
secreted in a pro form, which is cleaved to the active
MMP9 by other MMPs, primarily MMP3. Inflammatory
cytokines such as IL-8 and TNFa [22,23] are known to
be involved in the regulation of the MMP9 system
through the induction of both MMP3 and MMP9. Also,
TNFa [41] and IL-1b [42] are examples of cytokines that
are actually activated by MMP9. Similar to MMP2, an
endogenous inhibitor of the proteolytic activity of MMP9
has been described, and is known as TIMP1. TIMP1 pro-
vides an additional level of regulation of proteolysis in
the brain and can be regulated, in turn, by inflammatory
factors and tissue redox balance [35,43].
The MMP9 system was assessed by qRT-PCR, ELISA,
zymography and immunohistochemistry in our Ab vacci-
nation study in APPSw/NOS2-/- mice. We found that
MMP3 gene and protein expression are robustly increased,
while MMP9 is increased to a lesser extent. TIMP1 levels
were reduced at the gene expression level and remain
unchanged at the protein level. A similar pattern was
observed at 2 and 3 months in the passive immunization
study. In addition, zymography revealed that MMP9 activ-
ity is significantly increased following Ab vaccination in
APPSw/NOS2-/- mice. Finally, MMP9 immunohisto-
chemistry showed a dramatic elevation of expression in
the endothelial cells of the cerebrovasculature in APPSw/
NOS2-/- mice receiving Ab vaccination compared to
those mice control vaccination.
In vitro MMP2 and MMP9 have both been shown
to proteolyze Ab [44,45]. Moreover, in vivo MMP9 is
increased in association with amyloid plaques in trans-
genic mouse models of amyloid deposition [46]. Addition-
ally, treatment of APP/PS1 mice with FK506 lowered Ab
and increased MMP9 suggesting a relationship between
elevated MMP9 and lower Ab [47]. However, in human
AD despite MMP9 being overexpressed around amyloid
deposits [48], MMP2, MMP3 or MMP9 cannot be asso-
ciated with plaque load in AD suggesting that they are not
crucial for the regulation of plaque load [49]. We believe
that the upregulation of MMPs in our immunotherapy
studies may play a small role in the clearance of Ab due to
immunotherapy but other clearance mechanisms are also
known to play a significant role (reviewed in [4]). Our data
in BV2 cells indicates that MMPs, especially the MMP9
system can be upregulated through Fcg receptor signaling
mechanisms more efficiently than Ab alone and this is
likely the primary mechanism for MMP upregulation in
our immunotherapy studies.
We have previously shown a robust inflammatory
response to anti-Ab immunotherapy, regardless of
whether an active vaccination or passive immunization
approach is used [50-54]. To determine whether the
inflammatory response to immunotherapy was, at least in
part, responsible for the increased MMP2 and MMP9
activities, we used BV2 microglial cells to determine how
immune complexes change the MMP expression. Treat-
ment of BV2 microglial cells with immune complexes of
anti-Ab IgG/Ab or anti-tau/tau significantly increased
MMP3 and MMP9, the two MMPs most closely asso-
ciated with inflammation. In contrast, we did not observe
significant changes in MMP3 or MMP9 with IgG alone or
Ab alone, indicating an Fcg-receptor mediated activation.
Conclusions
Overall, we believe that the inflammatory response to anti-
Ab immunotherapy leads to increased MMP activity by
increasing expression of two key proteolytic systems in the
brain. The elevation of MMP2 and MMP9 levels and
activity coupled with the restricted levels of endogenous
tissue inhibitors TIMP1 and TIMP2 strongly suggests a
shift in the MMP/TIMP ratio toward favoring active pro-
teolysis. Degradation of vascular basement membranes
and tight junction proteins are likely results of such a shift.
These data, plus published data describing the dependence
of cerebral hemorrhage on MMP9 activity, indicate that
increased MMP activity and resulting protein degradation
may be a factor in the increased incidence of microhemor-
rhage found with anti-Ab immunotherapy.
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